Maha Radhakrishnan
Executive Partner, Private Equity,
Sofinnova Investments
United States
Maha is an accomplished industry executive.
Prior to joining Sofinnova in 2024, Maha was Consultant to the CEO at Dyne Therapeutics helping with the overarching strategy and direction to the company R&D and Commercialization efforts. Before Dyne, she was the Chief Medical Officer at Biogen, responsible for the Worldwide Medical function since rejoining Biogen in January 2020. Previously, from 2016-2019, Maha was Senior Vice President and Global Head of Medical, Primary Care Business Unit at Sanofi, a global biopharmaceutical company focused on human health. At Sanofi, she led the medical strategy and operations for the diabetes and cardiovascular products and development programs. Prior to this, she held several key leadership roles at Bioverativ Inc. from 2016-2018, Biogen for the first time from 2013-2016, Bristol Myers Squibb from 2009-2013, United Health Group from 2006-2008, and Cephalon from 2005-2006. Maha has overseen the launch preparations and execution of several blockbuster launches including Abilify, Orencia, Tecfidera, Praluent, Nusinersen, Qalsody, Leqembi, Skyclarys and Clinical Development including life cycle management of several critical programs in the Hemophilia, Immunology, Rare Disease, Cardiovascular and CNS Therapeutic areas.
Maha received her M.D. in internal medicine with honors from the People’s Friendship University in Moscow, Russia.
Suffix
MD
Sessions
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}